CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で19.23%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 37.06Mに達しています。
割高
同社の最新のPEは-1.91で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は16.20M株で、前四半期比で5.98%減少しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.51です。